Stockscreener 앱 받기
4.455
0.34%
0.015
Polypid Ltd 주식(PYPD)의 최신 뉴스
Aurum holds 5,001,561 shares in Polypid Ltd. (PYPD) with exercisable warrants - Stock Titan
AIGH Capital Management LLC Has $5.83 Million Stock Position in PolyPid Ltd. $PYPD - MarketBeat
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting - BioSpace
PolyPid to present wound infection data at surgery conference - Investing.com
PolyPid to present wound infection data at surgery conference By Investing.com - Investing.com Canada
PolyPid says late-stage surgery trial cut severe wound infections 64% - Stock Titan
PYPD Price Today: PolyPid Ltd. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Increases By 166.1% - MarketBeat
PYPD (PolyPid Ltd. Ordinary Shares) reports wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading.Pro Trader Recommendations - Cổng thông tin điện tử tỉnh Tây Ninh
PolyPid (PYPD) Stock Outlook | Q4 2025: Earnings UnderperformHigh Growth - Cổng thông tin điện tử tỉnh Lào Cai
PolyPid Ltd stock (US70450B1035): Is its drug-delivery tech strong enough to unlock biotech upside? - AD HOC NEWS
PolyPid Ltd stock (US70450B1035): Is its drug delivery tech strong enough to unlock surgical market - AD HOC NEWS
Nir Dror Darwish Net Worth (2026) - GuruFocus
Itzhak Krinsky Net Worth (2026) - GuruFocus
PolyPid (PYPD) Stock Recovery Underway (-1.27%) 2026-04-16Hot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Yechezkel Barenholz Net Worth (2026) - GuruFocus
Dikla Czaczkes Akselbrad Net Worth (2026) - GuruFocus
Jonathan Missulawin Net Worth (2026) - GuruFocus
Yitzchak Shlomo Jacobovitz Net Worth (2026) - GuruFocus
PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference - Sahm
PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026 - RTTNews
PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global By Investing.com - Investing.com Australia
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 - markets.businessinsider.com
PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global - Investing.com
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating - GlobeNewswire
Short Covering: How much upside does PolyPid Ltd have2026 Key Lessons & Weekly High Return Stock Forecasts - baoquankhu1.vn
In a Phase 3 surgery trial, PolyPid's antibiotic released for 32 days - Stock Titan
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short Interest - MarketBeat
PYPD Options Volatility — NASDAQ:PYPD - TradingView
PYPD Options Chain — NASDAQ:PYPD - TradingView
PolyPid (NASDAQ:PYPD) Stock Price Up 3.3%Still a Buy? - MarketBeat
Market Rankings: Is PolyPid Ltd likely to announce a buybackPortfolio Gains Summary & Smart Swing Trading Techniques - baoquankhu1.vn
PYPD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Gainers: Does PolyPid Ltd have high return on assets2026 Technicals & Target Return Focused Stock Picks - baoquankhu1.vn
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 earnings call transcript - MSN
PolyPid (PYPD) director submits initial Form 3 ownership - Stock Titan
PolyPid (PYPD) director details vested and future stock options - Stock Titan
Can PolyPid (PYPD) Stock Beat Estimates | Price at $4.24, Down 3.42%Aggressive Growth Stocks - Newser
Total equity of PolyPid Ltd. – FWB:2PV - TradingView
Total debt of PolyPid Ltd. – FWB:2PV - TradingView
PolyPid Ltd. Balance Sheet – FWB:2PV - TradingView
Cash per share of PolyPid Ltd. – FWB:2PV - TradingView — Track All Markets
PolyPid Ltd. Stock (2PV)Quote Deutsche Boerse AG - marketscreener.com
PolyPid Ltd.: Target Price Consensus and Analysts Recommendations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Revenue and Earnings Analysts Forecasts Revisions | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Financial Data Forecasts Estimates and Expectations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Shareholders Board Members Managers and Company Profile | IL0011326795 - marketscreener.com
PolyPid Ltd.: Fundamental Analysis and Financial Ratings | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Performance & Quotes, 2PV Stock Price on Deutsche Boerse AG Exchange - marketscreener.com
Taxes of PolyPid Ltd. – FWB:2PV - TradingView
2PV: Static price chart | PolyPid Ltd. | IL0011326795 - marketscreener.com
PYPD Trades Sideways: Key Levels in Focus - Newser
Net income of PolyPid Ltd. – FWB:2PV - TradingView
2PV Stock Price and Chart — FWB:2PV - TradingView
PolyPid’s Moment Is Here: NDA Submission Begins as a High-Impact Catalyst Stack Takes Shape (NASDAQ: PYPD) - The Globe and Mail
PolyPid begins rolling NDA submission for surgical infection drug By Investing.com - Investing.com South Africa
PYPD Should I Buy - Intellectia AI
Polypid Ltd Initiates D-Plex100 Nda Submission to Fda - MarketScreener
Risk Check: Does PolyPid Ltd stock benefit from AI growth2026 Performance Recap & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Polypid initiates D-Plex100 NDA submission to the FDA - marketscreener.com
PolyPid begins rolling NDA submission for surgical infection drug - Investing.com
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA - Bitget
0.83%
2.04%
자본화:
|
볼륨(24시간):